Engineered immune cells take aim at aggressive bone marrow cancer
NCT ID NCT03455972
First seen Mar 29, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study tests whether specially engineered T cells (CAR T cells) that target two proteins on cancer cells (CD19 and BCMA) can safely control high-risk multiple myeloma after a stem cell transplant. About 43 participants will receive the CAR T cells and be monitored for side effects and how long the cancer stays away. The goal is to improve outcomes for people with an aggressive form of this blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND EFFICACY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.